Nanoparticle for DSA Removal
NCT04277377 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2025-08-28
Summary
Magnetic nanoparticles, coated with human leukocyte antigens (HLA) to capture anti-HLA antibodies with donor specificity (donor-specific antibodies, DSA), will be tested ex-vivo.
Conditions
- Kidney Failure
- Presence of Donor Specific Antibodies
Sponsors & Collaborators
-
University of Zurich
lead OTHER
Principal Investigators
-
Beatrice Beck Schimmer, Prof · University of Zurich
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-10-05
- Primary Completion
- 2026-02-28
- Completion
- 2026-02-28
Countries
- Switzerland
Study Locations
More Related Trials
-
Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy
NCT05847920 ·Status: TERMINATED ·Phase: PHASE2
-
Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
NCT02197767 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome
NCT05704400 ·Status: RECRUITING ·Phase: PHASE2
-
PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease
NCT01581073 ·Status: COMPLETED ·Phase: PHASE3
-
Dara-BCD for Rare MGRS
NCT06771180 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
NCT04492722 ·Status: TERMINATED ·Phase: PHASE2
-
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)
NCT01322347 ·Status: COMPLETED ·Phase: PHASE3
-
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)
NCT02966717 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Telitacicept in Patients With Refractory IgA Nephropathy
NCT05596708 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)
NCT02363946 ·Status: TERMINATED ·Phase: PHASE1
-
Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant
NCT01502267 ·Status: UNKNOWN ·Phase: PHASE2
-
Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)
NCT00656799 ·Status: COMPLETED ·Phase: PHASE3
-
Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria
NCT05718375 ·Status: COMPLETED ·Phase: PHASE2
-
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
NCT01320202 ·Status: COMPLETED ·Phase: PHASE3
-
Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis
NCT00004990 ·Status: COMPLETED ·Phase: PHASE2
-
A Study With Imlifidase in Anti-GBM Disease
NCT05679401 ·Status: TERMINATED ·Phase: PHASE3
-
Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients
NCT04428008 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients
NCT00529633 ·Status: TERMINATED ·Phase: PHASE3
-
Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia
NCT05745883 ·Status: COMPLETED ·Phase: PHASE1
-
A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine
NCT01031966 ·Status: COMPLETED ·Phase: PHASE2
-
Modified Autologous Leukocyte Cells for the Treatment of Acute Kidney Injury After Cardiac Surgery
NCT07052513 ·Status: RECRUITING ·Phase: PHASE2
-
An Outcome Analysis of Primary Membranous Nephropathy
NCT06242327 ·Status: RECRUITING
-
Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis
NCT00548249 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
NCT05174221 ·Status: COMPLETED ·Phase: PHASE1